Efficacy of Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma: a Multicenter, Observational, Real-world Study
Latest Information Update: 26 Mar 2024
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Camrelizumab (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary) ; Toripalimab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 26 Mar 2024 New trial record